A phase 1 study of prasugrel in patients with sickle cell disease: Effects on biomarkers of platelet activation and coagulation - Jakubowski, Joseph A.; Zhou, Chunmei; Jurcevic, Stipo; Winters, Kenneth J.; Lachno, D. Richard; Frelinger, Andrew L.; Gupta, Neehar; Howard, Jo; Payne, Christopher D.; Mant, Timothy G. (Thrombosis research, 2014)
Keywords: Adenosine Diphosphate - metabolism; ADP; Adult; Anemia, Sickle Cell - drug therapy; Anemia, Sickle Cell - metabolism; Biomarkers; Biomarkers - metabolism; Blood Coagulation - drug effects; Blood Platelets - drug effects; Blood Platelets - metabolism; Female; Hematology, Oncology and Palliative Medicine; Humans; Male; Middle Aged; P2Y12 receptor antagonist; Piperazines - therapeutic use; Platelet Activation - drug effects; Platelets; Prasugrel; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists - therapeutic use; Sickle cell disease; Thiophenes - therapeutic use; Young Adult; CD40L; RBCs; GPIIbIIIa; VOC; EDTA; ADP; P2Y12 receptor antagonist; Prasugrel; SD; TF; TXB2; PD; SCD; Biomarkers; PK; Platelets; Sickle cell disease; red blood cells; tissue factor; P2Y 12 receptor antagonist; pharmacodynamics; glycoprotein IIb-IIIa; sickle cell disease; vaso-occlusive crisis; thromboxane B 2; adenosine diphosphate; ethylenediaminetetraacetic acid; pharmacokinetics; TXB 2; CD40 ligand; standard deviation; thromboxane B; P2Y receptor antagonist; TXB